Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/23/2025 | Hold → Buy | Erste Group | |
5/13/2025 | $153.00 | Outperform → Market Perform | Leerink Partners |
12/10/2024 | $166.00 | Neutral | BofA Securities |
11/15/2024 | $190.00 | Outperform | Wolfe Research |
7/23/2024 | $160.00 → $150.00 | Outperform → Neutral | Daiwa Securities |
5/30/2024 | $160.00 | Neutral | Goldman |
4/18/2024 | $170.00 | Hold → Buy | HSBC Securities |
12/13/2023 | $170.00 → $163.00 | Overweight → Equal Weight | Wells Fargo |
Erste Group upgraded Johnson & Johnson from Hold to Buy
Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00
BofA Securities resumed coverage of Johnson & Johnson with a rating of Neutral and set a new price target of $166.00
For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin
For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not
For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione
10-Q - JOHNSON & JOHNSON (0000200406) (Filer)
13F-HR - JOHNSON & JOHNSON (0000200406) (Filer)
8-K - JOHNSON & JOHNSON (0000200406) (Filer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
3 - JOHNSON & JOHNSON (0000200406) (Issuer)
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Dean Omar Branham Shirley attorneys secure verdict by linking mesothelioma to asbestos in J&J talc products A Boston jury has sided with Paul and Kathryn Lovell in a lawsuit against cosmetic behemoth Johnson & Johnson (NYSE:JNJ) that asserted Mr. Lovell's mesothelioma was directly caused by the company's iconic, asbestos-laced baby powder. The jury awarded $42,609,300, making it what lawyers believe to be the largest mesothelioma verdict in Massachusetts history. During the two-week trial, jurors heard compelling arguments from Dean Omar Branham Shirley attorneys Aaron Chapman and Danny Kraft, who detailed how Johnson & Johnson and its affiliated entities knowingly concealed for decades
Early VIRTUGUIDE™ surgeons report a 30-minute reduction in surgical time versus traditional treatment1,2,*,** WEST CHESTER, Penn., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson MedTech, a global leader in orthopaedic technologies and solutions, today announced the launch of the VIRTUGUIDE™ System. This AI-powered, patient-matched solution is designed to support Lapidus procedures2, a type of bunion surgery that helps realign the foot by joining two bones near the arch (the first metatarsal bone and the medial cuneiform).3 The system uses pre-operative planning software, developed in collaboration with PeekMed®, to assess each patient's bunion and make persona
Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated with TREMFYA®, the only dual-acting IL-23 inhibitor HORSHAM, Pa., July 29, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval to include new evidence in the TREMFYA® (guselkumab) label for the inhibition of progression of structural damage in adults with active psoriatic arthritis (PsA). The submission is s
4 - JOHNSON & JOHNSON (0000200406) (Issuer)
Johnson & Johnson (NYSE:JNJ) announced today that Daniel Pinto, President, JPMorganChase, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610707025/en/ "We are thrilled to have Daniel join Johnson & Johnson's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is an exceptional leader with deep financial expertise and understanding of global capital markets. Daniel's unique perspective and wealth of experience will be a tremendous asset to Johnson & Johnson as we continue to invest in and advance the next generation of healthcare inno
WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), a clinical-stage specialty immunotherapy biotech company leveraging AI-driven immunotherapy drug discovery, today announced the appointment of David E. Banko, CPA, a leading expert with three decades of industry experience in market access and health policy, to its leadership team as Global Head of Government Affairs and Patient Access. In this critical role, Mr. Banko will spearhead market access strategies in collaboration with R&D across Tevogen's growing product portfolio in oncology, virology, neurology, and rheumatology to advance and support commercial readines
Jessica Moore Appointed Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine Johnson & Johnson (NYSE:JNJ) (the "Company") today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has served as Vice President, Investor Relations since 2021, will assume the role of Group Chief Financial Officer, Johnson & Johnson, Innovative Medicine. The new appointments are effective May 1, 2025, and Mr. Snellgrove as well as Ms. Moore, will continue to report to Johnson & Johnson's Executive Vice President and Chief Financial Officer, Joseph Wolk. "Today's announcement reflects the deep bench of talent within Johnson & Johnson as well
Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po
2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b
Johnson & Johnson (NYSE:JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson's executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay o
SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)
SC 13G/A - JOHNSON & JOHNSON (0000200406) (Subject)